Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHEK Check-Cap	$0.64 -1.2%	$0.73	$0.56 ▼ $3.04	$3.77M	0.19	25,977 shs	2,612 shs
DRCT Direct Digital	$0.41 +3.6%	$0.53	$0.38 ▼ $6.59	$8.94M	6.04	762,633 shs	118,928 shs
SLGL Sol-Gel Technologies	$25.80 +40.2%	$10.68	$4.01 ▼ $26.89	$51.26M	1.21	22,397 shs	114,815 shs
SLS SELLAS Life Sciences Group	$1.76 -4.9%	$1.79	$0.77 ▼ $2.27	$194.80M	2.26	1.79 million shs	1.70 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHEK Check-Cap	-1.68%	-5.15%	-14.59%	-24.42%	-66.28%
DRCT Direct Digital	+1.04%	-13.47%	-24.33%	-11.93%	-87.89%
SLGL Sol-Gel Technologies	+3.72%	+19.09%	+118.53%	+139.43%	+309.80%
SLS SELLAS Life Sciences Group	+8.82%	+19.74%	0.00%	+5.11%	+41.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHEK Check-Cap	0.4037 of 5 stars	0.0	3.0	1.7	0.0	0.6
DRCT Direct Digital	2.4839 of 5 stars	3.3	3.0	1.3	2.5	0.6
SLGL Sol-Gel Technologies	1.0889 of 5 stars	0.0	3.0	4.0	1.7	0.0
SLS SELLAS Life Sciences Group	2.8547 of 5 stars	3.5	2.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHEK Check-Cap	0.00	N/A	N/A	N/A
DRCT Direct Digital	2.50	Moderate Buy	$6.00	1,359.14% Upside
SLGL Sol-Gel Technologies	0.00	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	297.73% Upside

Current Analyst Ratings Breakdown

Latest SLGL, CHEK, DRCT, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/8/2025	DRCT Direct Digital	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHEK Check-Cap	N/A	N/A	N/A	N/A	$4.05 per share	N/A
DRCT Direct Digital	$62.29M	0.15	N/A	N/A	($1.09) per share	-0.38
SLGL Sol-Gel Technologies	$11.54M	6.24	N/A	N/A	$11.44 per share	2.26
SLS SELLAS Life Sciences Group	$1M	185.33	N/A	N/A	$0.25 per share	7.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHEK Check-Cap	-$17.57M	-$3.00	N/A	∞	N/A	N/A	N/A	N/A	N/A
DRCT Direct Digital	-$6.24M	-$1.83	N/A	N/A	N/A	-25.99%	N/A	-36.29%	N/A
SLGL Sol-Gel Technologies	-$10.58M	-$1.23	N/A	N/A	N/A	-14.25%	-11.80%	-9.39%	N/A
SLS SELLAS Life Sciences Group	-$30.88M	-$0.32	N/A	N/A	N/A	N/A	-132.51%	-92.79%	N/A

Latest SLGL, CHEK, DRCT, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	SLGL Sol-Gel Technologies	-$0.67	$4.17	+$4.84	$4.17	$2.86 million	$17.26 million
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	-$0.07	+$0.0067	-$0.07	N/A	N/A
8/5/2025	Q2 2025	DRCT Direct Digital	-$0.96	-$0.23	+$0.73	-$0.23	$11.84 million	$10.14 million
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A
DRCT Direct Digital	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHEK Check-Cap	N/A	N/A	N/A
DRCT Direct Digital	N/A	0.49	0.49
SLGL Sol-Gel Technologies	N/A	7.32	5.12
SLS SELLAS Life Sciences Group	N/A	4.91	4.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHEK Check-Cap	1.07%
DRCT Direct Digital	4.02%
SLGL Sol-Gel Technologies	26.18%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
CHEK Check-Cap	0.48%
DRCT Direct Digital	62.82%
SLGL Sol-Gel Technologies	66.51%
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHEK Check-Cap	80	5.85 million	5.82 million	Not Optionable
DRCT Direct Digital	60	22.52 million	8.37 million	Not Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable
SLS SELLAS Life Sciences Group	10	105.30 million	103.82 million	Not Optionable

SLGL, CHEK, DRCT, and SLS Headlines

Recent News About These Companies

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

August 20 at 11:47 AM | marketbeat.com

SELLAS Life Sciences Group Target of Unusually High Options Trading (NASDAQ:SLS)

August 20 at 3:09 AM | americanbankingnews.com

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

August 19 at 10:09 PM | seekingalpha.com

SELLAS Life Sciences Group (NASDAQ:SLS) Issues Earnings Results

August 14, 2025 | marketbeat.com

Sellas Life Sciences Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

Sellas Life Sciences reports Q2 EPS (7c), consensus (8c)

August 12, 2025 | msn.com

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ...

August 9, 2025 | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

August 7, 2025 | globenewswire.com

SELLAS Life Sciences Group (SLS) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

July 31, 2025 | zacks.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 1.8% - What's Next?

July 31, 2025 | marketbeat.com

Sellas Flat on Trial Success

July 16, 2025 | baystreet.ca

SELLAS gains as mid-stage trial for leukemia drug succeeds

July 16, 2025 | msn.com

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL, CHEK, DRCT, and SLS Company Descriptions

Check-Cap NASDAQ:CHEK

$0.64 -0.01 (-1.24%)

Closing price 03:41 PM Eastern

Extended Trading

$0.64 0.00 (0.00%)

As of 06:10 PM Eastern

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Direct Digital NASDAQ:DRCT

$0.41 +0.01 (+3.55%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 +0.00 (+0.92%)

As of 07:27 PM Eastern

Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.

Sol-Gel Technologies NASDAQ:SLGL

$25.80 +7.40 (+40.22%)

Closing price 04:00 PM Eastern

Extended Trading

$25.10 -0.70 (-2.69%)

As of 07:55 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

SELLAS Life Sciences Group NASDAQ:SLS

$1.76 -0.09 (-4.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 +0.00 (+0.23%)

As of 08:00 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time